


PHARMACEUTICAL 2020

Rasna Therapeutics Inc. Rank 95 of 362





PHARMACEUTICAL 2020

Rasna Therapeutics Inc. Rank 95 of 362

The relative strengths and weaknesses of Rasna Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rasna Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 126% points. The greatest weakness of Rasna Therapeutics Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 65% points.

The company's Economic Capital Ratio, given in the ranking table, is -27%, being 275% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	72
Cost of Goods Sold	0
Intangible Assets	2,723
Liabilities, Current	2,405
Liabilities, Non-Current	0
Other Assets	2,149
Other Compr. Net Income	0
Other Expenses	294
Other Liabilities	3.0
Other Net Income	-29
Property and Equipment	1.9
Research and Development	14
Revenues	0
Selling, General and Administrative Expense	599

Output Variable	Value in 1000 USD
Assets	4,946
Liabilities	2,409
Expenses	908
Stockholders Equity	2,537
Net Income	-936
Comprehensive Net Income	-936
Economic Capital Ratio	-27%